You can buy or sell ASMB and other stocks, options, ETFs, and crypto commission-free!
Assembly Biosciences, Inc. Common Stock, also called Assembly Biosciences, is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. Read More It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
52 Week High
52 Week Low
Seeking AlphaFeb 28
Assembly Biosciences misses by $0.08, revenue in-line - Assembly Biosciences, Inc. (NASDAQ:ASMB)
Markets InsiderFeb 28
Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results
SAN FRANCISCO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results for the fourth quarter and year ended December 31, 2018. “Assembly has achieved many significant milestones over the past year across both our HBV and microbiome programs,” stated Derek Small, President and Chief Executive Officer ...
Stock Price, News, & Analysis for Assembly Biosciences
Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a plat...
Expected May 7, After Hours